Moderate riskFDA DrugClass II

Payless Compounders semaglutide injectable recalled for sterility concerns

Payless Compounders is recalling a compounded semaglutide injection due to lack of assurance of sterility. The affected product is a 0.5 mL vial from lot 01-27-2026@14S.5 distributed in Oregon. No injuries have been reported so far.

From the FDA notice · Read the official notice ↗

What to do

  1. Stop using this product immediately if you have it
  2. Contact your pharmacy or healthcare provider with the lot number
  3. Do not use remaining doses from the affected lot
  4. Ask your provider about alternative treatment options

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Sold in
OR
Made for
Adults (0 months and older)

Details

Units affected
91 vials
Illnesses reported
None reported
Manufactured in
8505 Sw Creekside Pl Ste 110, N/A, Beaverton, OR, United States
Classification
Class II
Recall number
D-0471-2026

In the FDA's words

Description
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR Lack of Assurance of Sterility Lot Number 01-27-2026@14S.5 Distribution: OR Affected quantity: 91 vials
Hazard
Lack of Assurance of Sterility

Related topics